Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Recruiting 4Completed 4Active not recruiting 3Terminated 2Enrolling by invitation 1Available 1Approved for marketing 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 3

Conditions

Recurrence 2Lymphoma, Mantle-Cell 2Lymphoma, B-Cell 1

Interventions

Cyclophosphamide 1499Cisplatin 1434Paclitaxel 1339Radiotherapy 1310Carboplatin 1266Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 697Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × brexucabtagene autoleucel × Clear all
NCT02625480 2026-04-09

ZUMA-4

Gilead Sciences

Phase 1/2 Completed
95 enrolled
Lymphoid

Recurrence, Lymphoma, B-Cell

NCT02601313 2026-03-18

ZUMA-2

Gilead Sciences

Phase 2 Completed
105 enrolled 33 charts 1 FDA
Lymphoid

Lymphoma, Mantle-Cell

NCT04880434 2025-11-17

ZUMA-2

Gilead Sciences

Phase 2 Completed
95 enrolled
Lymphoid

Lymphoma, Mantle-Cell

NCT02614066 2024-11-19

ZUMA-3

Gilead Sciences

Phase 1/2 Completed
125 enrolled 27 charts 1 FDA

Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡